Viewing nowJardiance 10 mg (Empagliflozin)
Empagliflozin 10mg
Tablet · Prescription medication
Hana Pharmaceutical Co., Ltd.

MFDS item code 202102090 · Approved 2021.03.05 · Insurance code 657808330
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It can also be administered as monotherapy, and in cases where patients have never been treated with diabetes medications or have difficulty controlling blood sugar with monotherapy, it can be used in combination with metformin. Additionally, it may be combined with other treatments such as metformin alone, pioglitazone, sulfonylureas, or insulin therapy for patients whose blood sugar control is insufficient. Caution is needed regarding the impact of this medication on cardiovascular event occurrence in patients with cardiovascular diseases and type 2 diabetes; therefore, refer to professional guidance. Overall, this medication is effectively used to improve blood sugar control in various situations.
The recommended dose of this medicine is 10 mg once daily, both as monotherapy and as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated but additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, section 3. Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations •Patients with renal impairment No dose adjustment is necessary for patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well and whose glomerular filtration rate remains below 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. Discontinue this medicine if the glomerular filtration rate decreases to below 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. This medicine should not be used in patients with end-stage renal disease (ESRD) or patients on dialysis, as efficacy is not expected. •Patients with hepatic impairment No dose adjustment is necessary for patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment because it has not been studied in this population. •Older adults No dose adjustment is necessary based on age. Renal function and the risk of volume depletion should be considered in patients aged 75 years or older. Initiating treatment with this medicine is not recommended in patients aged 85 years or older because clinical experience is limited (see Precautions for Use, section 4. General Precautions).
This medication should not be used in patients who are allergic to the active ingredient or any component of this medication. It should not be administered to patients with type 1 diabetes or diabetic ketoacidosis. This medication is not used in patients with severely impaired renal function or end-stage kidney disease, as well as those undergoing dialysis. Since this medication contains lactose, patients with genetic metabolic disorders such as lactose intolerance or galactose intolerance should not take it. Patients with mild renal impairment should be administered this medication with caution and renal function must be monitored before administration and regularly thereafter. For patients with severe heart failure, this medication is not recommended, while mild patients should use it cautiously. When used together with insulin or sulfonylureas, the risk of hypoglycemia may increase, so dosage adjustments may be required. During administration, patients should carefully observe for symptoms such as hypoglycemia, infections, increased urination, urinary tract infections, or decreased fluid volume, among other side effects. Particular attention should be given to severe infection symptoms such as genital infections and necrotizing fasciitis, and related symptoms require immediate consultation with medical personnel. This medication can induce ketoacidosis, so if symptoms such as vomiting, abdominal pain, or breathing difficulties occur, immediate medical attention is required. Elderly patients or those at risk of fluid loss should take precautions against dehydration and low blood pressure, and may temporarily discontinue use if necessary. Patients taking this medication should use alternative methods for monitoring blood sugar levels, as 1,5-AG tests are unreliable. Women who are pregnant or planning to become pregnant should avoid this medication, and breastfeeding women should refrain from taking it. Children under 18 years of age should not use this medication as its safety and efficacy have not been established for this age group. There have been no reports of specific toxic symptoms from overdose, but clinical condition should be meticulously monitored, and appropriate treatment should be provided as necessary. Store this medication out of the reach of children, and do not transfer it to other containers for safety. This medication may have a slight impact on driving or operating machinery, especially for patients at risk of hypoglycemia, so caution is advised. Diabetes patients should pay attention to routine foot care and it is important to consult medical personnel regarding the possibility of lower limb amputation.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it must be stored in a tightly sealed container. It is important to maintain a storage temperature between 1 and 30 degrees Celsius. By doing so, the medication's efficacy can be well maintained, ensuring safe use.
Light yellow, double-sided, convex, round film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowEmpagliflozin 10mg
Tablet · Prescription medication
Hana Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.